Minimal change disease associated with anti-PD1 immunotherapy: a case report

Oncologic immunotherapy is a form of therapy intended to reactivate the immune response to tumor cells using agents that modulate immune checkpoints, such as programmed cell death protein 1 and its ligand (PD-...

Source: BMC Nephrology - July 3, 2018 Category: Urology & Nephrology Authors: Bixia Gao, Ningjing Lin, Suxia Wang and Yu Wang Tags: Case report Source Type: research